Appendix 1. Inclusion and Exclusion Criteria

Inclusion Criteria

1. Providing written informed consent prior to any study-related procedures being performed. Patients from 12 through 17 years old could participate where permitted by applicable local regulations and IRB approval and with appropriate documentation of consent from the parent(s)/guardian(s) and assent from the patient.
2. Clinical diagnosis of BV, defined as having all of the following:
    a) Off-white (milky or gray), thin, homogeneous discharge with minimal or absent pruritus and inflammation of the vulva and vagina
    b) The presence of clue cells > 20% of the total epithelial cells on microscopic examination of the saline wet mount
    c) Vaginal secretion pH of > 4.5
    d) A fishy odor of the vaginal discharge with the addition of a drop of 10% KOH (i.e., a positive whiff test)
3. No known medical conditions that, in the investigator's opinion, could interfere with study participation.
4. Agree to abstain from sexual intercourse and/or sexual activity throughout the first 7 days following treatment.

Mauck C, Hillier SL, Gendreau J, Dart C, Chavoustie S, Sorkin-Wells V, et al. Single-Dose, bioadhesive, clindamycin 2% gel for bacterial vaginosis: A Randomized Controlled Trial. Obstet Gynecol 2022;139.
The authors provided this information as a supplement to their article.
©2022 American College of Obstetricians and Gynecologists.

5. Nonpregnant patients of childbearing potential were to use adequate birth control after Day 7 if engaging in heterosexual intercourse, and were not to plan on becoming pregnant for the duration of the study. Acceptable forms of birth control included oral contraceptives, intrauterine devices, contraceptive implants, transdermal patches, injections, and nonpolyurethane condoms (e.g., latex, polyisoprene) with or without spermicide. Patients in same sex relationships, or monogamous relationships with vasectomized males, could also participate. Abstinence could also be acceptable, per the investigator's judgment.

   Patients who were not of childbearing potential did not need a urine pregnancy test prior to randomization or at subsequent visits. The patient was considered to be of nonchildbearing potential if one of the following was satisfied:

   a) Postmenopausal for at least 1 year prior to the screening/randomization visit (Visit 1) (defined as amenorrheic for more than one continuous year), or

   b) Surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) at least 6 months before first dose, or

   c) Nonsurgical permanent sterilization procedure performed at least 3 months prior to study drug application.

6. Willing to refrain from the use of all intravaginal products (e.g., douches, feminine deodorant sprays, condoms, spermicides, vaginal moisturizers or lubricants, tampons,

©2022 American College of Obstetricians and Gynecologists.

contraceptive vaginal rings, and diaphragms) through the first 7 days at a minimum, and ideally through Visit 3 or study exit/early discontinuation.

Exclusion Criteria

1. Active vulvovaginitis or other active infectious causes of cervicitis, vaginitis, or vulvitis, based on the results of the thorough clinical assessments and in-clinic microscopic assessments performed prior to enrollment (e.g., candidiasis, *T. vaginalis*, *C. trachomatis*, *N. gonorrhoeae*, or genital lesions or ulcers consistent with human papillomavirus [HPV], Herpes simplex virus, syphilis, chancroid, etc.). Patients with a history of genital herpes or condylomata who had been asymptomatic for at least 6 months could be considered for eligibility.
2. Breastfeeding or, if of childbearing potential, unwilling to practice acceptable means of birth control or abstinence during the study as described above.
3. Vaginal, vulvar, or genitourinary condition that, according to the investigator's judgment, could confound the interpretation of clinical response.
4. History of regional enteritis, ulcerative colitis, or *Clostridium difficile*-associated diarrhea.
5. Known current drug or alcohol abuse that could impact study compliance.
6. Currently receiving or who had received antifungal or antibacterial therapy (systemic or intravaginal) within 14 days of the screening/randomization visit.

©2022 American College of Obstetricians and Gynecologists.

7. Use of any other investigational product within 30 days of the screening/randomization visit.
8. Planned evaluation or treatment during the study for abnormal cytology and/or findings from high-risk HPV testing and/or Pap test finding.
9. Known sensitivity to clindamycin phosphate or other lincosamides or any of the inactive ingredients in the study drug.
10. History of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with study participation or study drug administration or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.

©2022 American College of Obstetricians and Gynecologists.

Appendix 2. Summary of Analysis Populations (Intent-To-Treat Population)

Analysis Population	Clindamycin (N = 204) n (%)	Placebo (N = 103) n (%)	Total (N = 307) n (%)
Intent-to-Treat (ITT)	204 (100.0)	103 (100.0)	307 (100.0)
Safety	203 (99.5)	103 (100.0)	306 (99.7)
Modified Intent-to-Treat (mITT)	122 (59.8)	59 (57.3)	181 (59.0)
Per Protocol (PP)	102 (50.0)	47 (45.6)	149 (48.5)

©2022 American College of Obstetricians and Gynecologists.

Appendix 3. Summary of Adverse Events by System Organ Class and Preferred Term (Safety Population)

	Clindamycin (N = 203)		Placebo (N = 103)		Total (N = 306)	
System Organ Class Preferred Term	Events n	Subjects n (%)	Events n	Subjects n (%)	Events n	Subjects n (%)
Number of Events, Number (%) of Subjects with at Least One AE	107	76 (37.4)	42	28 (27.2)	149	104 (34.0)
Blood and lymphatic system disorders	2	2 (1.0)	0	0	2	2 (0.7)
Anemia	1	1 (0.5)	0	0	1	1 (0.3)
Lymphadenopathy	1	1 (0.5)	0	0	1	1 (0.3)
Ear and labyrinth disorders	1	1 (0.5)	0	0	1	1 (0.3)
Ear pain	1	1 (0.5)	0	0	1	1 (0.3)
Gastrointestinal disorders	7	6 (3.0)	2	2 (1.9)	9	8 (2.6)
Abdominal pain	2	2 (1.0)	1	1 (1.0)	3	3 (1.0)
Abdominal pain lower	1	1 (0.5)	0	0	1	1 (0.3)
Constipation	1	1 (0.5)	0	0	1	1 (0.3)
Diarrhea	2	2 (1.0)	1	1 (1.0)	3	3 (1.0)
Gastroesophageal reflux disease	1	1 (0.5)	0	0	1	1 (0.3)
General disorders and administration site conditions	1	1 (0.5)	0	0	1	1 (0.3)
Pyrexia	1	1 (0.5)	0	0	1	1 (0.3)
Infections and infestations	54	46 (22.7)	22	15 (14.6)	76	61 (19.9)
Bacterial vaginosis	3	3 (1.5)	3	3 (2.9)	6	6 (2.0)

©2022 American College of Obstetricians and Gynecologists.

	Clindamycin (N = 203)		Placebo (N = 103)		Total (N = 306)	
System Organ Class Preferred Term	Events n	Subjects n (%)	Events n	Subjects n (%)	Events n	Subjects n (%)
Bacterial vulvovaginitis	0	0	2	1 (1.0)	2	1 (0.3)
COVID-19	1	1 (0.5)	0	0	1	1 (0.3)
Genital herpes	1	1 (0.5)	0	0	1	1 (0.3)
Herpes zoster	1	1 (0.5)	0	0	1	1 (0.3)
Papilloma viral infection	0	0	1	1 (1.0)	1	1 (0.3)
Pelvic infection	0	0	1	1 (1.0)	1	1 (0.3)
Pelvic inflammatory disease	0	0	2	2 (1.9)	2	2 (0.7)
Pharyngitis streptococcal	1	1 (0.5)	0	0	1	1 (0.3)
Trichomoniasis	4	4 (2.0)	2	2 (1.9)	6	6 (2.0)
Urinary tract infection	6	6 (3.0)	5	5 (4.9)	11	11 (3.6)
Vaginal infection	0	0	2	1 (1.0)	2	1 (0.3)
Vulvovaginal candidiasis	37	35 (17.2)	4	4 (3.9)	41	39 (12.7)
Injury, poisoning and procedural complications	1	1 (0.5)	0	0	1	1 (0.3)
Skin laceration	1	1 (0.5)	0	0	1	1 (0.3)
Investigations	1	1 (0.5)	2	2 (1.9)	3	3 (1.0)
Alanine aminotransferase increased	0	0	1	1 (1.0)	1	1 (0.3)
Blood creatinine increased	1	1 (0.5)	0	0	1	1 (0.3)
Blood pressure increased	0	0	1	1 (1.0)	1	1 (0.3)
Metabolism and nutrition disorders	1	1 (0.5)	0	0	1	1 (0.3)
Type 2 diabetes mellitus	1	1 (0.5)	0	0	1	1 (0.3)

©2022 American College of Obstetricians and Gynecologists.

	Clindamycin (N = 203)		Placebo (N = 103)		Total (N = 306)	
System Organ Class Preferred Term	Events n	Subjects n (%)	Events n	Subjects n (%)	Events n	Subjects n (%)
Nervous system disorders	4	2 (1.0)	1	1 (1.0)	5	3 (1.0)
Ageusia	1	1 (0.5)	0	0	1	1 (0.3)
Anosmia	1	1 (0.5)	0	0	1	1 (0.3)
Headache	1	1 (0.5)	1	1 (1.0)	2	2 (0.7)
Somnolence	1	1 (0.5)	0	0	1	1 (0.3)
Reproductive system and breast disorders	30	23 (11.3)	12	10 (9.7)	42	33 (10.8)
Cervical dysplasia	0	0	1	1 (1.0)	1	1 (0.3)
Cervical friability	0	0	1	1 (1.0)	1	1 (0.3)
Cervix disorder	0	0	1	1 (1.0)	1	1 (0.3)
Menstruation irregular	1	1 (0.5)	0	0	1	1 (0.3)
Pelvic pain	1	1 (0.5)	0	0	1	1 (0.3)
Vaginal discharge	3	3 (1.5)	0	0	3	3 (1.0)
Vaginal hemorrhage	5	5 (2.5)	4	4 (3.9)	9	9 (2.9)
Vulva cyst	1	1 (0.5)	0	0	1	1 (0.3)
Vulval disorder	1	1 (0.5)	0	0	1	1 (0.3)
Vulvovaginal burning sensation	3	3 (1.5)	2	2 (1.9)	5	5 (1.6)
Vulvovaginal discomfort	1	1 (0.5)	1	1 (1.0)	2	2 (0.7)
Vulvovaginal dryness	2	1 (0.5)	0	0	2	1 (0.3)
Vulvovaginal erythema	2	2 (1.0)	0	0	2	2 (0.7)
Vulvovaginal pruritus	10	9 (4.4)	2	2 (1.9)	12	11 (3.6)

Mauck C, Hillier SL, Gendreau J, Dart C, Chavoustie S, Sorkin-Wells V, et al. Single-Dose, bioadhesive, clindamycin 2% gel for bacterial vaginosis: A Randomized Controlled Trial. Obstet Gynecol 2022;139.
The authors provided this information as a supplement to their article.
©2022 American College of Obstetricians and Gynecologists.

	Clindamycin (N = 203)		Placebo (N = 103)		Total (N = 306)	
System Organ Class Preferred Term	Events n	Subjects n (%)	Events n	Subjects n (%)	Events n	Subjects n (%)
Respiratory, thoracic and mediastinal disorders	2	2 (1.0)	0	0	2	2 (0.7)
Cough	1	1 (0.5)	0	0	1	1 (0.3)
Nasal congestion	1	1 (0.5)	0	0	1	1 (0.3)
Skin and subcutaneous tissue disorders	2	2 (1.0)	3	3 (2.9)	5	5 (1.6)
Drug eruption	0	0	1	1 (1.0)	1	1 (0.3)
Intertrigo	0	0	1	1 (1.0)	1	1 (0.3)
Miliaria	1	1 (0.5)	0	0	1	1 (0.3)
Rash papular	1	1 (0.5)	0	0	1	1 (0.3)
Skin lesion	0	0	1	1 (1.0)	1	1 (0.3)
Surgical and medical procedures	1	1 (0.5)	0	0	1	1 (0.3)
Tooth extraction	1	1 (0.5)	0	0	1	1 (0.3)

Note: Subjects reporting more than one AE in each SOC/PT are only counted once to that SOC/PT in the column of 'Subjects'.

AEs coding dictionary: MedDRA Version 23.0.

©2022 American College of Obstetricians and Gynecologists.

Appendix 4. Relationship Between Candida Culture at Screening and Candidiasis Treatment-Emergent Adverse Events (Safety Population)

	Clindamycin			Placebo		
	Candidiasis TEAE	No candidiasis TEAE	Total	Candidiasis TEAE	No candidiasis TEAE	Total
Positive *Candida* culture at screening	18	24	42	2	17	19
Negative *Candida* culture at screening	17	140	157	2	82	84
Total	35	164	199	4	99	103

Note - Table does not include 4 clindamycin patients with unknown *Candida* culture at screening.

©2022 American College of Obstetricians and Gynecologists.

Appendix 5. Summary of Clinical Cure, Bacteriological Cure, and Therapeutic Cure (Intent-to-Treat Population)*

	Clindamycin (N = 122) n (%)	Placebo (N = 59) n (%)	Total (N = 307) N (%)
Parameter at the Test of Cure (TOC) Visit – day 21-30			
Clinical Cure	143 (70.1)	38 (36.9)	105 (33.2)
95% CI for the Percentage	(63.6 - 76.6)	(27.1 - 46.7)	(21.2 - 45.2)
Bacteriological Cure (Nugent score < 4)	79 (38.7)	13 (12.6)	92 (30.0)
Therapeutic Cure	71 (34.8)	11 (10.7)	82 (26.7)
Parameter at the Interim Assessment Visit – day 7-14			
Clinical Cure	154 (75.5)	37 (35.9)	191 (62.2)
Bacteriological Cure (Nugent score < 4)	82 (40.2)	10 (9.7)	92 (30.0)
Therapeutic Cure	69 (33.8)	8 (7.8)	77 (25.1)

*P-values from CMH test <0.001 for all rows

©2022 American College of Obstetricians and Gynecologists.